secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2023-05-30T23:59:59+00:00
Accession:  0001558370-23-010565
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix announces FDA and EU approval of Elfabrio for Fabry disease; investor event June 27
--------------------------------------------------------------------------------

- Elfabrio (pegunigalsidase alfa) approved in both US and EU for adult Fabry disease patients.
- Commercial partner Chiesi Global Rare Diseases is prepared for launch.
- In-person investor event scheduled for June 27, 2023 at Lotte Palace Hotel, New York City.
- CEO Dror Bashan highlights ProCellEx platform and pipeline programs for future growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023010565/0001558370-23-010565-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023010565/plx-20230530x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-010565

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer